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Introduction: The assessment of B-type natriuretic peptide (BNP) plasma levels is not only
useful for the differential diagnosis of acute dyspnea, but also for the prognostic stratiﬁcation
of patients with heart failure. However, available studies that have addressed monitoring of
hospitalized patients are burdened with signiﬁcant limitations: (1) measurement of plasma
BNP levels only at admission or at discharge, (2) lack of details regarding the cause of heart
failure, and (3) small sample size. Therefore, we conducted a prospective study of all patients
presenting to our hospital with acutely decompensated chronic systolic heart failure.
Aim: To determine the importance of admission and discharge values of BNP and its changes
during hospitalization for identiﬁcation of patients with acutely decompensated chronic
systolic heart failure at higher risk of unfavorable course of the disease.
Methods: A prospective monocentric study determining plasma BNP levels at admission and at
discharge in patients hospitalized for acutely decompensated chronic systolic heart failure.
Patients: 130 consecutive patients, 77% men, mean age 70 years, body mass index (BMI) 27.8 kg/
m2; etiology of chronic heart failure—65.9% ischemic heart disease, 29.5% dilated cardiomyo-
pathy, 4.6% others; signs and symptoms at admission—peripheral edema 58.9%, pulmonary
rates 88.3%, orthopnea 53.1%, median of admission BNP 1101 pg/ml, median of discharge BNP
650 pg/ml, median left ventricular ejection fraction 26.5%, average length of hospitalization
9 days.
Results: During the follow-up (mean 15months) the total mortality rate reached almost 40% and
the annual mortality of our cohort was 29%. The most common causes of death included
progression of heart failure and acute coronary syndromes. To evaluate the long-term risk ofch Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
Internal Medicine and Cardiology, University Hospital Brno, Jihlavska 20, 625 00 Brno,
20 532232611.
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c o r e t v a s a 5 5 ( 2 0 1 3 ) e 2 8 6 – e 2 9 2 e287mortality, we used time-dependent ROC curves for the deﬁnition of cut-off values of BNP at
admission and discharge. The relationship of BNP levels and the survival of patients was
assessed using the hazard ratio (HR) calculated by the Cox proportional hazards model. BNPs at
admission and at discharge with a cut-off value of 1699 pg/ml and 434.5 pg/ml are signiﬁcant
prognostic factors for patients hospitalized for acutely decompensated chronic systolic heart
failure with a HR 2.79 and 3.29, respectively. During the follow-up, more than half of the
patients required readmission to the hospital. The most common reasons for rehospitalization
were cardiovascular causes.
Conclusion: BNP levels at admission and at discharge are an important predictive factor of
survival in patients with acutely decompensated chronic systolic heart failure.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.1. Introduction
Increasing average age of the population and signiﬁcant
improvement in the treatment of acute coronary syndromes
are the main factors leading to constant increase in preva-
lence and incidence of the heart failure [1]. Number of
hospitalizations in developed countries increased almost four
times during the last 20 years. Acute heart failure is one of
the most common causes of hospitalization in 65+ patients
and it is associated with very poor prognosis [2,3]. Approxi-
mately 45% of patients with acute heart failure require
rehospitalization within 1 year [4]. In-hospital mortality
ranges from 4% [5] to 29% [6], 1-year mortality from 29% [7]
to 51% [6] and according to Sosin, approximately 90% of
patients hospitalized for acute heart failure die within
8 following years. It is, therefore, important to assess the
prognosis of patients with acute heart failure. Currently,
several factors associated with prognosis of these patients
are identiﬁed based on age, gender, systolic and diastolic left
ventricular function, renal functions, hemoglobin concentra-
tion, level of natrium and others.
Plasma levels of natriuretic peptides or their fragments
belong to the most important predictive markers identifed up
to date. Assessment of BNP and NT-proBNP (N-terminal
fragment of B-type natriuretic peptide) is helpful not only
for differential diagnosis of acute dyspnea but also for
assessment of prognosis in patients with heart failure. This
has been proven by several previous studies [8], which,
however, bear some limitations. Most of the studies were
carried out among ambulatory patients with chronic heart
failure. Studies that observed hospitalized patients were
often retrospective, natriuretic peptides levels were mea-
sured only at admission or at discharge, they concerned only
small number of patients and did not distinguish between
patients with systolic and diastolic heart failure [9–12]. There-
fore, in this study we decided to assess plasma levels of BNP
in patients hospitalized for acutely decompensated chronic
systolic heart failure both on their admission and discharge.2. Material and methods
The aim of this single-center, prospective study of patients
with acutely decompensated chronic systolic heart failurewas to evaluate the importance of admission and discharge
values of BNP and its changes during the hospitalization as a
risk factor of an unfavorable course of the disease.
All patients older than 18 years with the diagnosis of
acutely decompensated chronic systolic heart failure and
requiring intravenous therapy, admitted to Department of
Internal Medicine and Cardiology, University Hospital Brno,
who fulﬁlled the diagnostic criteria of European Society of
Cardiology (2005) and signed the informed consent, were
included in the study. History of chronic heart failure longer
than 3 months and left ventricle ejection fraction (LVEF)
lower than 45% (assessed within last 6 months) were com-
prised in the inclusion criteria. The exclusion criteria were:
acute coronary syndromes, right heart failure caused primar-
ily by pulmonary disease, history of heart transplantation or
presence on the heart transplant waiting list, unstable angina
pectoris or coronary artery disease requiring cardiac surgery
(CABG) or percutaneous coronary intervention prior to the
study, history or presence of any other disease with survival
prognosis shorter than 3 years, presence of hemodynamically
signiﬁcant mitral stenosis or mitral regurgitation except
for the mitral regurgitation secondary to dilatation of left
ventricle, hemodynamically signiﬁcant aortic stenosis or
regurgitation, hemodynamically signiﬁcant obstruction of left
ventricular outﬂow tract and non-compliance of the patient.
All patients underwent complete clinical examination
(medical history, physical examination) and laboratory tests
including the measurement of plasma levels of BNP at admis-
sion and before discharge from hospital. Conventional clinical
examination including basic physical measurements and
necessary laboratory tests were performed during the hospi-
talization and the patients were monitored and treated
according to the standards for acute heart failure and with
regard to their clinical state. Blood pressure was measured
conventionally using the automatic manometer OMRON M7
following the current guidelines of Czech Society of Cardiology
from 2008. On the admission day, electrocardiography (ECG)
and chest X-ray were performed. Transthoracic echocardio-
graphy at rest was performed on GE Healthcare Vivid 7 device
with M4S probe from standard views (parasternal long and
short axis, apical two- and four-chamber positions and sub-
costal position) after clinical stabilization of the patient, prior
to discharge. Dimensions were calculated as an average value
from three measurements. LVEF was calculated by means of
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Fig. 1 – Kaplan–Meier curve for total mortality rate.
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Fig. 2 – Kaplan–Meier curve for cardiovascular mortality.
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Fig. 3 – Mortality curve for BNP cut-off at admission.
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c o r e t v a s a 5 5 ( 2 0 1 3 ) e 2 8 6 – e 2 9 2e288Simpson's method. Entire therapy protocol from the admis-
sion to discharge was recorded for each patient. BNP levels
measurement was performed in a certiﬁed laboratory of Depart-
ment of Clinical Biochemistry, University Hospital Brno, within
20min from blood sample collection. Axsym sets by Abbott
were used for BNP assessment. The blood drawn was a part of
common blood sample collections within hospitalization and
was conducted under standard conditions from the cubital vein.
Patients willing to and capable of regular ambulatory check-ups
were followed-up in our outpatient department for heart failure.
Information of possible death and its cause in non-followed up
patients was acquired from ÚZIS database.
Personal data security was guaranteed by assigning a trial
number for each patient in the study. All data were recorded in
an electronic form, and processed in the Institute of Biostatis-
tics and Analyses of Masaryk University Brno, using a standard
descriptive statistics. Continuous variables are expressed as
median and 5th and 95th percentile, and categorical variables
as absolute and relative counts. Basic descriptive analysis of all
variables was used to assess differences between genders; thesedifferences were tested using the Mann–Whitney U test for
continuous variables and ML chi-square test for categorical
variables. For long-term mortality risk evaluation, time-
dependent ROC curves were used to determine optimal cut-
off values for individual parameters. The relation of parameters
to survival rate was evaluated using the hazard ratio (HR)
calculated in Cox proportional hazards model. Kaplan–Meier
curve was employed to depict patient survival. P values o0.05
were considered as signiﬁcant, and were corrected for multiple
testing. Statistical analyses were performed using software
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Fig. 4 – Mortality curve for BNP cut-off at discharge.
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c o r e t v a s a 5 5 ( 2 0 1 3 ) e 2 8 6 – e 2 9 2 e289package SPSS 18.0.2 and Statistica 9.1. The study was approved
by Ethics Committee of University Hospital Brno, and all
patients provided an informed consent.3. Results
A total of 130 patients (77% males, 23% females) were
included in the study, basic population characteristics are
shown in Tables 1 and 2. Women were older than men (77.0
vs 68 years, p¼0.014); other basic characteristics data did not
differ signiﬁcantly between men and women with the excep-
tion of weight at admission (87.0 vs 75.0 kg, p¼0.002) and at
discharge (82.9 vs 72.5 kg, p¼0.022). Fifty nine percent of
patients had peripheral edema, 30% had jugular venous
distention and 88.3% of patients presented with clinical signs
of pulmonary congestion on admission. Fifty three percent of
patients reported orthopnea. All patients had left-ventricular
systolic dysfunction and three quarters of patients had left-
ventricular diastolic dysfunction. On admission, more than
80% of patients showed signs of pulmonary congestion on
chest X-ray and almost half of the patients had pleural
effusions. Mean cardiothoracic ratio was 60%. The most
common comorbidities in medical history of patients were
hypertension (81.4%), diabetes mellitus type 2 (62%) and
hyperlipoproteinemia (58.1%), and also high incidence of
atrial ﬁbrillation is not negligible (40.3%). This was, however,
only paroxysmal in almost half of the cases (paroxysmal 46%,
persistent 6%, permanent 48%). From other comorbidities,
15.5% of patients had chronic obstructive pulmonary disease,
14.7% had ischemic disease of lower limbs; chronic renalfailure was present in 27.1%, cerebrovascular disease in 20.9%
and anemia in 9.3% of patients. Concerning the etiology of
chronic heart failure, ischemic heart disease prevailed with
65.9% against dilated cardiomyopathy (29.5%) and other
cardiomyopathies (chemotherapy-induced cardiomyopathy,
tachycardia-induced cardiomyopathy and post-
inﬂammatory cardiomyopathy). Anamnestic data did not
differ signiﬁcantly between men and women with the excep-
tion of the incidence of hypertension (85.9 vs 66.7%, p¼0.024)
and atrial ﬁbrillation (35.4 vs 56.7%, p¼0.036). Biochemical
characteristics for the patient population are shown in
Table 1. Apart from the difference in hemoglobin concentra-
tion (137.5 vs 124.0 g/l, p¼0.027), there was no other signiﬁ-
cant difference in biochemical parameters between men and
women. Statistically signiﬁcant decrease in BNP level during
the hospitalization period (po0.001) has been recorded. Tro-
ponin T was positive in more than one third of patients in the
frame of acute decompensated heart failure; this was without
any connection to acute coronary syndrome. Almost three
quarters of patients used long-term renin–angiotensin–aldos-
terone blockers (RAAS) and beta blockers. The use of these
groups of medication was mildly higher at discharge in
comparison to the admission. There was a statistically sig-
niﬁcant increase in number of patients treated by loop
diuretics and mineralocorticoid receptors antagonists.
Although more than 40% of our patients suffered from atrial
ﬁbrillation, only approximately 24% of them were on oral
anticoagulation therapy. Table 2 shows selected intravenous
pharmacotherapy during hospitalization and selected non-
pharmacological therapy during hospitalization. Most of the
patients were treated by intravenous loop diuretics during
the hospitalization: median of administration was 4 days (5;
95 percentile—1.00; 8.00) and median of cumulative dose of
intravenous furosemide was 300 mg (5; 95 percentile—60.0;
2700.0). The most frequently used positive inotropic agent
was dobutamine followed by levosimendan. Target dose of
levosimendan (0.2 μg/kg/min) was achieved only in 25% of
patients. The mean length of hospitalization was 9 days (5; 95
percentile—5.0; 22.0). Pulmonary edema was reported in
24.6% of patients and cardiogenic shock in 2.4% of patients;
the rest of patients had mild heart failure according to the
Killip/Forrester classiﬁcation (73.0%) with predominant back-
ward failure of the left ventricle, with no obvious inducing
factor. Infections were found among the most common in-
hospital complications, especially infections of respiratory
tract. Weight loss, decrease of blood pressure and heart rate
were recorded during hospitalization.
The mean length of the follow-up of patients hospitalized
for acutely decompensated systolic heart failure was 15
months (Table 3). During the follow-up almost 40% of
patients died. Cardiovascular disease was one of the most
common causes of death (69.1%). Figures 1 and 2 show
Kaplan–Meier curves for total death rate and death from
cardiovascular causes.
The aim of our study was to assess admission and
discharge values of BNP and its changes during the hospita-
lization and their relation to the risk-stratiﬁcation of the
patients with acute decompensated systolic heart failure.
For the assessment of the long-term mortality risk, time-
dependent ROC curves were applied to determine the cut-off
Table 1 – Characteristics of patients—continuous variables.
Admissiona During hospitalizationa Dischargea
Age at admission (years) 70.0(50.0;85.0) – –
BMI (kg/m2) 27.8(21.5;37.8) – 24.0(23.0;180.0)
Weight (kg) 84.0(59.0;116.0) – 81.0(55.0;106.0)
SBP (mmHg) 130.0(90.0;190.0) – 120.0(95.0;150.0)
DBP (mmHg) 80.0(60.0;100.0) – 70.0(60.0;90.0)
HR (/min) 90.0(60.0;125.0) – 70.0(58.0;95.0)
LVEF (%) – 26.5(15.0;43.0) –
EDV (ml) – 192.0(102.0;326.0) –
ESV (ml) – 138.0(61.0;253.0) –
LVMi (g/m2) – 130.2(87.8;219.6) –
LAVoli (ml/m2) – 53.2(27.9;83.3) –
E/Em average (sep, lat) – 18.7(7.1;40.8) –
Sodium (mmol/l) 140.0(133.0;146.0) – –
Glycemia (mmol/l) 6.30(4.10;16.70) – –
Fasting glycemia (mmol/l) – 6.30(4.30;11.80) –
Troponin T peak (μg/l) – 0.04(0.00;0.37) –
Hemoglobin (g/l) 135.5(105.0;164.0) – –
BNP (pg/ml) 1101(290;3996) – 650(100;3298)
BNP adm−dis difference (pg/ml) −449(−2.884;318)
BNP adm−dis difference (in %) −46(−86;31)
GFR (ml/min/1.73m2) 54.0(24.7;91.8) 46.7(16.3;75.9)b 53.3(21.4;86.8)
CTR (%) 60(47;65) – –
BMI—Body mass index, SBP—systolic blood pressure, DBP—diastolic blood pressure, HR—heart rate, LVEF—left ventricular ejection fraction,
EDV—end-diastolic volume of left ventricle, ESV—end-systolic volume of left ventricle, LVMi—left ventricular mass index, LAVoli—left atrium
volume index, E/Em (sept, lat)—peak velocity of early diastolic ﬁlling of mitral inﬂow/peak early diastolic velocity of the septal and lateral
mitral anulus, adm—admission, dis—discharge, GFR—glomerular ﬁltration according to MDRD formula, CTR—cardiothoracic ratio.
a Values are presented as median and 5.-95. percentile.
b Minimal value during hospitalization.
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variables to survival was established using the hazard ratio
(HR) calculated in Cox proportional hazards model (Table 4).
BNP on admission and at discharge are signiﬁcant risk factors
for survival of the patients with acute decompensated sys-
tolic heart failure. Cumulative survival rates for these cut-offs
are shown in Figures 3 and 4. Fifty ﬁve percent of the patients
were rehospitalized during the follow-up period. Cardiovas-
cular causes were among the most frequent reasons for
rehospitalization (78.4%).4. Discussion
A continuous increase in incidence of heart failure which is
connected with poor prognosis has been reported recently.
One-year mortality in our study reached 29% which is con-
sistent with literary sources [7]. The most common cause of
death was a progression of heart failure and acute coronary
syndromes. Almost 55% of patients were rehospitalized dur-
ing the follow-up period, in accordance with previously
published data [4].
There are no clear guidelines for discharging patients with
acutely decompensated chronic systolic heart failure. The
improvement of clinical symptoms achieved with the ther-
apeutic adjustment is the most important decision-making
factor today. According to the literature, the BNP levels at
discharge correlated more precisely with the outcomes thanlevels on admission [9–11]. Because BNP levels can be inﬂu-
enced by the therapy [13–16], serial evaluations of BNP may
be useful in deﬁning a safe timing of discharge. However, an
evaluation of the therapy effect on BNP levels was not the
purpose of our study.
Simple identiﬁcation of patients with successful hospital
treatment of acutely decompensated chronic systolic heart
failure could help to develop the rules for hospital discharge
strategies. Currently there are no generally accepted clear
prognostic cut-off values of admission or discharge BNP
plasma level; not even absolute or relative change of BNP level
during hospitalization in patients hospitalized for acutely
decompensated chronic systolic heart failure. Cut-off value of
BNP at discharge in our study (434.5 pg/ml) corresponds rela-
tively well with values associated with poor prognosis in
comparison but smaller study population groups [10,17].
Another signiﬁcant predictor of poor prognosis in our study
was BNP level on admission with a cut-off value of 1699 pg/ml.
These data support the simultaneous use of admission and
discharge BNP levels and its change for prognostic stratiﬁcation.
Decrease in plasma level of BNP of less than 64% was associated
with risk of death with HR 1.45 in our study. It did not reach
statistical signiﬁcance but, again, this cut-off value corresponds
with the levels associated with poor prognosis in a relatively
comparable study population [17].
Our results prove that the changes in neurohumoral
activation are associated with changes in mortality and
suggest another possible use for BNP, a cheap and widely
Table 2 – Characteristics of patients—categorical variables.
Admissiona During hospitalizationa Dischargea
Diastolic function of left ventricle Not available – 17(13.1%) –
Normal – 13(10.0%) –
Dysfunction – 100(76.9%) –
Pleural effusion Yes 44(45.4%) – –
PC (chest X-ray) Yes 90(80.4%) – –
SR Yes 75(58.1%) – –
LBBB Yes 50(38.8%) – –
RBBB Yes 12(9.3%) – –
ACEI Yes 77(60.6%) – 84(66.7%)
ARB Yes 20(15.7%) – 18(14.3%)
BB Yes 92(72.4%) – 108(85.7%)
Furosemide Yes 84(66.1%) – 123(99.2%)
Spironolactone Yes 66(52.0%) – 108(85.7%)
HCTH Yes 16(12.6%) – 8(6.3%)
Statins Yes 71(55.9%) – 88(69.8%)
ASA Yes 69(54.3%) – 80(63.5%)
ADP Yes 9(7.1%) – 15(11.9%)
Warfarin Yes 30(23.6%) – 30(23.8%)
Digoxin Yes 34(26.8%) – 33(26.2%)
Amiodarone Yes 36(28.3%) – 40(31.7%)
Noradrenaline i.v. Yes – 9(7.0%) –
Adrenaline i.v. Yes – 1(0.8%) –
Dobutamine i.v. Yes – 14(10.9%) –
Dopamine i.v. Yes – 4(3.1%) –
Levosimendan i.v. Yes – 12(9.3%) –
Nitrates i.v. Yes – 30(23.3%) –
Diuretics i.v. Yes – 121(93.8%) –
NIPV Yes – 8(6.2%) –
APV Yes – 3(2.3%) –
IABP Yes – 0(0.0%) –
TPM Yes – 1(0.8%) –
HD/CVVH Yes – 1(0.8%) –
AKI Yes – 6(4.7%) –
ALI Yes – 2(1.6%) –
Malignant arrhythmias Yes – 3(2.3%) –
CPR Yes – 4(3.1%) –
Infections Yes – 32(24.8%) –
In-hospital mortality Yes – 3(2.3%) –
Cause of death Cardiac – 2(66.7%) –
Non-cardiac – 1(33.3%) –
PC—Pulmonary congestion, SR—sinus rhythm, LBBB—left bundle branch block, RBBB—right bundle branch block, ACEI—angiotensin-
converting enzyme inhibitor, ADP—ADP receptors blocker, ARB—angiotensin II receptor blocker, ASA—acetylsalicylic acid, BB—beta blocker,
HCTH—hydrochlorothiazide, i.v.—intravenous, NIPV—non-invasive pulmonary ventilation, APV—artiﬁcial pulmonary ventilation, IABP—
intra-aortic balloon counterpulsation, TPM—temporary pacemaker, HD/CVVH—hemodialysis/continuous veno-venous hemoﬁltration, ALI—
acute liver injury, AKI—acute kidney injury, CPR—cardiopulmonary resuscitation.
a Values are presented as numbers of patients and percentage.
Table 3 – Follow-up period (months).
N Mean Median 5. percentile 95. percentile
Total 127 15.15 13.23 1.25 32.36
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as a guide for stratiﬁcation of patients with acutely decom-
pensated chronic systolic heart failure allowing to select a
group in need of more intensive treatment during hospitali-
zation and could be also useful in deﬁning a safe timing for
discharge.This study suggests a clinically applicable data for man-
agement and risk stratiﬁcation of patients with acutely
decompensated chronic systolic heart failure. However,
it was a single-center study and therefore, our cut-off cannot
be extrapolated without conduction of more studies that are
needed to identify the best cutt-off and percent variations.
Table 4 – BNP cut-off values for long-term mortality.
Cut-off AUC (95% CI) Sensitivity; speciﬁcity HR (95% CI)a p
BNP adm (pg/ml) ≥1699 0.62(0.51;0.68) 0.54;0.73 2.79(1.58;4.91) o0.001b
BNP dis (pg/ml) ≥434.5 0.67(0.56;0.79) 0.83;0.53 3.29(1.37;7.90) 0.008b
BNP adm–dis difference (pg/ml) ≤982 0.56(0.42;0.61) 0.41;0.78 1.62(0.82;3.20) 0.166
BNP adm–dis difference (%) ≤64.0 0.52(0.44;0.63) 0.87;0.28 1.45(0.63;3.31) 0.379
BNP—B-type natriuretic peptide, adm—admission, dis—discharge.
a Hazard ratio generated by Cox proportional hazards model.
b Statistically signiﬁcant difference.
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Our results strongly suggest that BNP levels on admission and
at discharge are a signiﬁcant prognostic factor in patients
hospitalized for acutely decompensated chronic systolic heart
failure. The cut-off values were 1699 pg/ml on admission and
434.5 pg/ml at discharge with HR 2.79 and 3.29, respectively. In
our study, the BNP levels at discharge were a stronger predictor
of adverse outcomes than those on admission.6. Study limitations
All patients hospitalized in our department for acutely decom-
pensated chronic systolic heart failure fulﬁlling inclusion cri-
teria were included in our study; thus patient selection had
been reduced. However, certain selection prior to hospitaliza-
tion in our department could not be avoided (tertiary center—
Cardiology Department within University Hospital).Acknowledgments
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